NASDAQ:ARQT

Arcutis Biotherapeutics Stock News

Healthcare > Biotechnology

Buy ARQT

*Your capital is at risk

$21.35

+0.560 (+2.69%)

At Close: Jun 03, 2026

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

07:30am, Tuesday, 07'th Apr 2026

Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sa

Phocas Financial Corp. Sells 41,808 Shares of Arcutis Biotherapeutics, Inc. $ARQT

06:44am, Monday, 06'th Apr 2026

Phocas Financial Corp. cut its position in Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 39.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities an

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

04:00pm, Tuesday, 31'st Mar 2026

Arcutis today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

11:00am, Saturday, 28'th Mar 2026

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

08:00am, Wednesday, 18'th Mar 2026

WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful i

Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT

03:31am, Sunday, 15'th Mar 2026

Ally Bridge Group NY LLC bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC.

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

09:00am, Tuesday, 10'th Mar 2026

ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatment Children ages 2-5 who achieved disease clearance and who switched t

Intech Investment Management LLC Sells 35,672 Shares of Arcutis Biotherapeutics, Inc. $ARQT

05:01am, Monday, 09'th Mar 2026

Intech Investment Management LLC decreased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 41.3% in the third quarter, according to the company in its most recent 13F filing

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

09:00am, Thursday, 05'th Mar 2026

WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations i

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

08:00am, Tuesday, 03'rd Mar 2026

Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis ARQ-234 is a potent fusion-

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by